Duodenojejunal bypass (DJB) is a novel metabolic surgery based on the foregut hypothesis. The stomach size is reduced according to the patient’s weight, in addition, the first part of the small intestine along with 200 cm of the jejunum are bypassed in a rerouting operation. In this surgery 1st, part of the duodenum is joined with the bypassed portion of the jejunum. This operation has the obvious advantages of Roux-en-Y Gastric Bypass and does not cause significant weight loss and dumping.

This operation has a similar hormonal mechanism to ileal interposition. After this operation ghrelin levels come down as the fundus of the stomach is removed. GLP 1 and Peptide YY hormones increase as the food rapidly reaches the small intestine.